NCT07222969
A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
At risk: Primary completion moved 5 months later, primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 5 more changesShow less
- Eligibility criteria expanded, about 109 words
- Primary completion pushed from Apr 30, 2027 to Sep 30, 2027
- Study completion pushed from Jun 30, 2027 to Dec 30, 2027
- Study sites: 2 to 4
- Secondary endpoints: 9 to 3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Start date changed from estimate of Oct 30, 2025 to Jan 12, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of treatment-related adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and DLTs
Timeframe: From the first drug administration to 150 days after the last drug administration
MTD and/or RP2D based on the incidence and nature of DLTs
Timeframe: From the first drug administration to the last day of DLT observation period
Secondary (3)
Pharmacokinetic parameters
Preliminary anti-tumor activity
Immunogenicity parameters
Arms and interventions
VIB305 for Injection in Cohort 1Experimental
VIB305 for Injection does in Cohort 1 according to protocol
VIB305 for Injection in Cohort 2Experimental
VIB305 for Injection does in Cohort 2 according to protocol
VIB305 for Injection in Cohort 3Experimental
VIB305 for Injection does in Cohort 3 according to protocol
VIB305 for Injection in Cohort 4Experimental
VIB305 for Injection does in Cohort 4 according to protocol
VIB305 for Injection in Cohort 5Experimental
VIB305 for Injection does in Cohort 5 according to protocol
VIB305 for Injection in Cohort 6Experimental
VIB305 for Injection does in Cohort 6 according to protocol
Drugs: VIB305 for Injection
Sites
4 sites in 2 countries
China 3, Australia 1